ERBB2 and ovarian carcinoma: The JMJD3 demethylase inhibitor, GSK-J1, showed convincing potency in suppressing ovarian cancer by restoring H3K27 methylation at the HER2 oncogene promoter region and then suppressing its transcription (Zhang et al., 2020).